We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · October 03, 2019

CUP-mRCC Treated With VEGF-Targeted Therapy Is Valid, Feasible, and Safe

Clinical Genitourinary Cancer

 

Additional Info

Clinical Genitourinary Cancer
Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature
Clin Genitourin Cancer 2019 Feb 01;17(1)e32-e37, A Overby, L Duval, M Ladekarl, BE Laursen, F Donskov

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading